A regulatory perspective on the evaluation of hallucinogen drugs for human use

A regulatory perspective on the evaluation of hallucinogen drugs for human use

Abstract

In recent years, there is renewed interest in the study of various hallucinogens for their potential therapeutic effects. In the United States of America (USA), the abuse potential assessment of a drug is carried out as part of the general safety and efficacy evaluation of a drug. Additionally, the abuse potential assessment is taken under consideration in determining if a drug needs to be subject to controls to minimize the abuse of the drug once on the market. This assessment is conducted for all new drugs with central nervous system (CNS) activity, that are chemically or pharmacologically similar to other drugs with known abuse potential, or drugs that produce psychoactive effects predictive of abuse, such as euphoria and hallucinations. This paper describes the regulatory framework for evaluating the abuse potential of new drugs, with emphasis on hallucinogens. The paper discusses the role of the United States Food and Drug Administration (FDA) in the evaluation of the abuse potential of drugs and its role in drug control, and provides an overview of the controlled status of hallucinogens and the requirements to conduct research with Schedule I substances in the USA.

Calderon, S. N., Hunt, J., & Klein, M. (2017). A regulatory perspective on the evaluation of hallucinogen drugs for human use. Neuropharmacology. 10.1016/j.neuropharm.2017.11.028

Link to full text

By | 2018-01-16T10:56:48+00:00 24 November 2017|Tags: , , |